Trastuzumab in the treatment of advanced non-small-cell lung cancer: Is there a role? Focus on Eastern Cooperative Oncology Group Study 2598

Journal of Clinical Oncology

Volumn 22, Issue 7, 2004, Pages 1180-1187

  Langer, Corey J ^a   Stephenson, Patricia ^a   Thor, Ann ^a   Vangel, Mark ^a   Johnson, David H ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY;

AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; FATIGUE; GENE EXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; KIDNEY FUNCTION; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; ONCOGENE NEU; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; ADULT; AGED; FEMALE; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 2142762457     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.04.105     Document Type: Article

References (31)

1. Mountain C: A new international staging system for lung cancer. Chest 89:2253-2335, 1986
2. Johnson DH: Treatment strategies for metastatic non small-cell lung cancer. Clin Lung Cancer 1:34-11, 1999
3. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
4. Kelly K, Crowley J, Bunn PA, et al: A randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001
5. Scagliotti GV, DeMarinis F, Rinald M, et al: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 20:308a, 2001 (abstr 1227)
6. Weiner DB, Nordberg J, Robinson R, et al: Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res 50:421-425, 1990
7. Tsai CM, Chang KT, Perng RP, et al: Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with Her-2/ gene expression but not with ras gene mutations. J Natl Cancer Inst 85:857-901, 1993
8. Yu D, Wang SS, Dulski KM, et al: c-erbB-2/ overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res 54:3260-3266, 1994
9. Kern JA, Schwartz DA, Nordberg JE, et al: p185neu expression in human lung adenocarcinomas predict shortened survival. Cancer Res 50:5184-5187, 1990
10. Kern J, Tormey L, Weiner D, et al: Inhibition of human lung cancer cell line growth by an anti-p185 HER-2 antibody. Am J Respir Cell Mol Biol 9:448-454, 1993
11. Korrapati V, Gaffney M, Larsson LG, et al: Effect of HER2/ expression on survival in early stage non-small cell lung cancer. Proc Am Soc Clin Oncol 18:480a, 1999 (abstr 1851)
12. Skrepnik N, Araya JC, Qian Z, et al: Effects of anti-erbB-2 (HER-2/neu) recombinant oncotoxin AR209 on human non-small cell lung carcinoma grown orthotopically in athymic nude mice. Clin Cancer Res 2:1851-1857, 1996
13. Pegram M, Hsu S, Lewis G, et al: Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251, 1999
14. Pegram MD, Lopez A, Konecny G, et al: Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin Oncol 27:21-25, 2000 (6suppl 11)
15. Kumar R, Mandal M, Vadlamudi R: New insights into anti-HER-2 receptor monoclonal antibody research. Semin Oncol 27:84-91, 2000 (6 suppl 11)
16. Slamon D, Leyland-Jones B, Shah S, et al: Addition of herceptin (humanized anti- Her-2 antibody) to first line chemotherapy for HER-2 overexpressing metastatic breast cancer (HJER2/MBC) markedly increased anti cancer activity: A randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:989, 1998(abstr 377)
17. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
18. Norton L, Slamon DJ, Leyland-Jones B, et al: Overall survival (OS) advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody Herceptin in HER2-overexpressing (HER2+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 18:127a, 1999 (abstr 483)
19. Verma S, Butts CA, Au HJ, et al: Incidence of Her-2/ in advanced non-small cell lung cancer and response to platinum based chemotherapy. Proc Am Soc Clin One 20:347a, 2001 (abstr 1384)
20. Hirsch FR, Varella-Garcia M, Franklin WA, et al: Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 86:1449-1456, 2002
21. Nakamura H, Saji H, Ogata A, et al: Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer. Int J Cancer 103:61-66, 2003
22. Bunn PA, Helfrich B, Soriano AF, et al: Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in site hybridization and its relationship to invitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res 7:3239-3250, 2001
23. Johnson DH, Arteaga CL: Gefitnib in recurrent non-small cell lung cancer: An IDEAL trial? J Clin Oncol 21:2227-2229, 2003
24. Brabender J, Danenberg KD, Metzger R, et al: Epidermal growth factor receptor and HER2/neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Canc Res 7:1850-1855, 2001
25. Yarden Y, Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2:127-137, 2001
26. Zinner R, Glisson BS, Pisters KM, et al: Cisplatin and gemcitabine combined with herceptin in patients with HER- 2 overexpressing, untreated advanced non-small cell lung cancer (NSCLC): a phase II trial. Proc Am Soc Clin Oncol 20:328a, 2001 (abstr 1307)
27. Tran HT, Herbst RS, Glisson BS, et al: Herceptin in combination with cisplatin and gemcitabine in patients with HER2 overexpressing, untreated, advanced NSCLC: Final report of a phase II trial. Proc Am Soc Clin Oncol 21:307a, 2002 (abstr 1226)
28. Gatzemeier J, Groth G, Hirsch F, et al: A randomized phase II study of gemcitabine/cisplatin alone and with herceptin in patients with HER-2-positive non-small cell lung cancer. Proc ECCO 37:S50, 2001 (abstr 173; suppl 6)
29. Gatzemeier U, Groth G, Butts C, et al: Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER-2 positive non-small-cell lung cancer. Ann Oncol 15:19-27, 2002
30. Krug LM, Miller VA, Crapanzano J, et al: Randomized phase II trial of trastuzumab plus either weekly docetaxel or paclitaxel in previously untreated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Onc 20:333a, 2001 (abstr 1328)
31. Patel JD, Krug LM, Crapanzano J, et al: Clinical characteristics and outcomes of patients with advanced NSCLC treated with trastuzumab plus either weekly docetaxel or paclitaxel. Proc am Soc Clin Oncol 21:305a, 2002 (abstr 1218)